Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity.

Details

Serval ID
serval:BIB_FAB8273FB0C1
Type
Article: article from journal or magazin.
Collection
Publications
Title
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity.
Journal
Nature medicine
Author(s)
Niessl J., Baxter A.E., Mendoza P., Jankovic M., Cohen Y.Z., Butler A.L., Lu C.L., Dubé M., Shimeliovich I., Gruell H., Klein F., Caskey M., Nussenzweig M.C., Kaufmann D.E.
ISSN
1546-170X (Electronic)
ISSN-L
1078-8956
Publication state
Published
Issued date
02/2020
Peer-reviewed
Oui
Volume
26
Number
2
Pages
222-227
Language
english
Notes
Publication types: Clinical Trial, Phase I ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Combination antiretroviral therapy (ART) is highly effective in controlling human immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a latent viral reservoir <sup>1,2</sup> . Potent broadly neutralizing antibodies (bNAbs) represent a potential alternative or adjuvant to ART. In addition to suppressing viremia, bNAbs may have T cell immunomodulatory effects as seen for other forms of immunotherapy <sup>3</sup> . However, this has not been established in individuals who are infected with HIV-1. Here, we document increased HIV-1 Gag-specific CD8 <sup>+</sup> T cell responses in the peripheral blood of all nine study participants who were infected with HIV-1 with suppressed blood viremia, while receiving bNAb therapy during ART interruption <sup>4</sup> . Increased CD4 <sup>+</sup> T cell responses were detected in eight individuals. The increased T cell responses were due both to newly detectable reactivity to HIV-1 Gag epitopes and the expansion of pre-existing measurable responses. These data demonstrate that bNAb therapy during ART interruption is associated with enhanced HIV-1-specific T cell responses. Whether these augmented T cell responses can contribute to bNAb-mediated viral control remains to be determined.
Keywords
Adult, Antibodies, Neutralizing/immunology, CD4-Positive T-Lymphocytes/immunology, CD4-Positive T-Lymphocytes/virology, CD8-Positive T-Lymphocytes/immunology, CD8-Positive T-Lymphocytes/virology, Epitopes/immunology, Female, Gene Products, gag/metabolism, HIV Antibodies/immunology, HIV Infections/immunology, HIV Infections/therapy, HIV Infections/virology, HIV-1, Humans, Immune System, Immunotherapy/methods, Interferon-gamma/immunology, Male, Middle Aged, T-Lymphocytes/immunology, T-Lymphocytes/virology, Viremia
Pubmed
Web of science
Open Access
Yes
Create date
09/05/2023 12:59
Last modification date
29/11/2024 17:17
Usage data